|
19 Apr 2025 |
Biocon
|
Consensus Share Price Target
|
331.30 |
380.95 |
- |
14.99 |
buy
|
|
|
|
|
25 May 2023
|
Biocon
|
ICICI Securities Limited
|
331.30
|
250.00
|
243.00
(36.34%)
|
Target met |
Hold
|
|
|
Biocon Limited’s (Biocon) Q4FY23 performance was boosted by consolidation of the acquired business of biosimilars (segment revenue up 114% YoY) from Viatris. Reported gross margin was inflated by ~150bps and EBITDA margin by 360bps due to licensing income of Rs1.75bn.
|
|
24 May 2023
|
Biocon
|
Motilal Oswal
|
331.30
|
260.00
|
243.00
(36.34%)
|
Target met |
Neutral
|
|
|
|
|
09 Mar 2023
|
Biocon
|
Geojit BNP Paribas
|
331.30
|
238.00
|
223.85
(48.00%)
|
Target met |
Hold
|
|
|
|
|
20 Feb 2023
|
Biocon
|
AUM Capital
|
331.30
|
260.00
|
227.70
(45.50%)
|
Target met |
Neutral
|
|
|
|
|
16 Feb 2023
|
Biocon
|
ICICI Direct
|
331.30
|
230.00
|
242.85
(36.42%)
|
Target met |
Hold
|
|
|
|
|
16 Feb 2023
|
Biocon
|
Axis Direct
|
331.30
|
260.00
|
242.85
(36.42%)
|
Target met |
Hold
|
|
|
Recommendation: We maintain HOLD on the stock
|
|
15 Feb 2023
|
Biocon
|
Motilal Oswal
|
331.30
|
250.00
|
238.10
(39.14%)
|
Target met |
Neutral
|
|
|
|
|
16 Nov 2022
|
Biocon
|
ICICI Securities Limited
|
331.30
|
362.00
|
284.40
(16.49%)
|
|
Buy
|
|
|
Biocon Limited’s (Biocon) Q2FY23 performance was ahead of our estimates led by better than expected results in the generics and research services. Generics revenue was up 17.5% YoY to Rs6.2bn while Research services delivered a robust growth of 25.9% YoY to Rs.7.7bn.
|
|
15 Nov 2022
|
Biocon
|
ICICI Direct
|
331.30
|
290.00
|
283.85
(16.72%)
|
Target met |
Hold
|
|
|
|
|
15 Nov 2022
|
Biocon
|
Axis Direct
|
331.30
|
310.00
|
283.85
(16.72%)
|
|
Hold
|
|
|
Management indicated that R&D costs will increase in the upcoming quarters which may pose threat to the current margins of the company. We, therefore, recommend a HOLD rating on the stock with a TP of Rs 310/share.
|